Peter Attia· MD
I think the evidence is strong enough that I take it / recommend it.
Verbal pushback — no audited source on record.
90
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I think the evidence is strong enough that I take it / recommend it.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Senolytic compounds clear senescent cells and extend healthspan in mice; human trials remain preliminary.
Monthly fisetin pulses clear senescent cells in humans at a clinically meaningful level.
The dasatinib + quercetin senolytic protocol improves frailty markers in older adults at 2-day-per-month dosing.